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Abstract 
 
Background: 
There remains uncertainty on the need for bone staging in men with intermediate-risk 
prostate cancer. Current guidelines do not use mpMRI-staging information and rely on 
historic pathology grading. 
Methods:  
We investigated the ability of mpMRI and the new Grade Group system to better predict 
bone metastasis status in a retrospective cohort-study of 438 men with prostate cancer 
undergoing baseline mpMRI and isotope bone scintigraphy(BS).  
Results: 
Including mpMRI-staging information significantly increased the specificity of bone 
metastasis detection from 3.0% to 24.2%(p<0.01) and sensitivity from 89.2% to 97.3%. The 
new Grade Group score demonstrated progressive increase in bone metastasis 
rates(p<0.001). A novel risk-stratification model combining Grade Groups, PSA and mpMRI-
staging shows promise in predicting bone metastasis and could potentially reduce BS usage 
by 22.4%-34.7%.  
Conclusions: 
Incorporating the new Grade Group system and mpMRI-staging more accurately identified 
bone metastatic risk and suggests men with Grade Group ≤2 and/or without radiological T3 
disease could safely avoid routine bone-staging. 
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Introduction 
Assessment of bone metastasis status is key for the management of prostate cancer 
(PCa)(NICE 2014a, Fizazi et al. 2015). Clear evidence exists for staging investigations such as 
isotope bone scintigrams (BS) in patients with high-risk PCa whilst precluding its routine use 
in low-risk disease(NICE 2014a). However, the utility of BS in intermediate-risk disease is 
unclear with EAU, AUA and NICE offering conflicting guidance(Heidenreich et al. 2014, NICE 
2014a).  
The International Society of Uro-Pathology (ISUP) have recently approved a new PCa ‘Grade 
Group’ classification system to improve correlation of Gleason grade to biochemical 
recurrence(Epstein et al. 2016). Concurrently, multiparametric (mp)-MRI has emerged as a 
crucial tool in local staging of PCa, allowing improved discrimination between T2 and T3 
disease compared to clinical nomograms(Turkbey et al. 2013, Lawrence et al. 2014). 
However, current guidelines on bone staging do not mandate use of mpMRI information or 
Grade Groups(NICE 2014a). Therefore, we investigated the ability of mpMRI-staging 
information or the new Grade Group system to help predict bone metastatic status and 
refine the use of bone staging investigations. 
 
Methods 
A radiology database was searched for all PCa patients undergoing baseline mpMRI prostate 
and BS from January 2010 - May 2015 in our tertiary centre(study registration CUH/3927). In 
cases of equivocal BS, the final status was recorded using a combination of clinical follow-up 
and/or any further radiological investigations. mpMRI was performed on a 3T Discovery 
MR750-HDx or 1.5T MR450 system (GE Healthcare, Waukesha, USA) with a surface phased-
array coil, including standard anatomical and functional diffusion-weighted imaging using 
multiple b-values, as previously described(Lawrence et al. 2014). All studies were reported 
by expert uro-radiologists and reviewed in a multi-disciplinary team (MDT) setting.  
Gleason score was assessed according to the ISUP 2005 recommendations (Epstein et al. 
2005) and recorded alongside the number of positive cores and percentage involvement of 
tissue. All cases were reported by a specialist uropathologist, and reviewed a second time by 
another uropatholigist prior to discussion at a specialist MDT. The core with the highest 
grade was used to devise the Grade Group.   
 
Patients were first categorised to low-(T1–T2a, Gleason ≤6 and PSA <10 ng/mL), 
intermediate-(T2b-c, and/or Gleason = 7 and/or PSA 10–20 ng/mL) and high-risk(T3-T4, or 
Gleason 8-10 or PSA level >20 ng/mL) according to NICE 2008 guidelines(NICE 2014b). 
Patients were subsequently re-categorised according to the new Grade Group 
system(Epstein et al. 2016) and a novel 5 stratum Risk Group system developed in our 
centre integrating PSA, Grade Group, and mpMRI staging (Gnanapragasam et al. 2016) 
(table 1).  
Contingency tables were constructed with expected frequency for bone metastasis and 
adjusted residuals calculated for each risk system. Pearson’s chi-squared test was used to 
examine the differences in observations. Comparison of sensitivities and specificities of 
bone metastasis between systems was made using McNemar’s test. To compare positive 
and negative predictive values, we used a generalised score statistic in R 3.1.2 (Leisenring et 
al. 2000, Stock and Hieschler 2014). All other statistical analysis was performed in Stata®14 
(StataCorp LP, Texas, USA). 
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Results 
438 patients underwent mpMRI and BS. Mean age (±SD) was 67.1 years (±6.7) and mean 
PSA 21.3 ng/ml (±48.1). In this cohort 37 patients had bone metastases (8.4%); Table 2. The 
specificity of BS was 86.5%. 14/37 (37.8%) men with bone metastases also had evidence of 
pelvic metastasis on prostate MRI. Using NICE intermediate-risk as a threshold for 
performing BS, 426 BS would have been performed. Assessing this risk-stratification as if it 
were a diagnostic test demonstrated a sensitivity of 100% but specificity of only 3.0%. 
Comparisons of other decision models were made against this standard (Table 3).  
 
Adding mpMRI to current NICE risk groups:  
The distribution of patients by NICE classification is shown in Table 2A. By these categories 
33/37 men with bone metastases were classified as high-risk and 4 as intermediate-risk. All 
4 intermediate-risk patients had PSA <20.0ng/mL but Gleason 4+3 disease. mpMRI staging 
re-categorised 3 of these patients to high-risk (eFigure 1&2), improving the sensitivity of 
high-risk for detecting bone metastases to 97.3% from 89.2%, and specificity compared to 
intermediate-risk to 24.2% from 3.0% (p<0.01). Using mpMRI-defined high-risk disease as a 
threshold for BS would have reduced the number of scintigrams performed by 98 (22.4%), 
with a single missed diagnosis. 
 
Applying the new Grade Group scores to predict bone metastases:  
Using the new Grade Group scores in isolation, there was a progressive increase in bone 
metastases detection from 0/43(0%) for Grade Group 1 to 20/121 (16.5%) for Grade Group 
5 (Gleason 9-10); p<0.001, Table 2B. Using BS only for patients with Grade Group scores ≥3 
significantly improved sensitivity to 97.3% and significantly improved specificity to 37.7% 
(p<0.01); Table 3. Using this cut-off would have reduced the number of BS by 152 (34.7%), 
with a single missed diagnosis. 
 
Combining mpMRI and Grade Group scores in a novel risk-stratification system:  
This model defines 5 prognostic risk strata for prostate cancer (Table 1)(Gnanapragasam et 
al. 2016). Within this model, no men in Risk Groups 1 or 2 had bone metastasis. Bone 
metastasis rate increased progressively in Risk Groups 3 (2.13%), 4 (5.8%) and 5 (13.7%); 
p=0.004. Using Risk Group 4 as a threshold for bone staging, demonstrated improvement in 
specificity to 23.9% (p<0.01) and 97.3% sensitivity, with a 22.1% reduction in the need for 
BS.  
 
Discussion  
Detection of bone metastasis confers a significantly worse prognosis in men with PCa and is 
thus an important part of the staging work-up(Fizazi et al. 2015). In our study we showed 
that only 8.4% of men had bone metastasis out of 438 men scanned, emphasising the need 
to refine use of this resource-intensive investigation. Of note, we did not find that a high 
PSA alone was a good discriminator; in our cohort we identified 4 men with bone 
metastases and a PSA <20ng/mL which is at odds with other reports(McArthur et al. 2012). 
  
In this study we have demonstrated evidence that mpMRI-staging provides a useful adjunct 
in appropriately identifying men who will benefit most from BS. The integration of mpMRI 
alongside traditional biochemical and pathological markers, to re-categorise patients as 
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high-risk disease, would have led to a 99.0% NPV for bone metastases at this threshold, 
alongside a significant increase in specificity to 24.2% and reduction in BS use. We also 
provide early validation of the new histological Grade Group system, with BS yield being 
higher in Grade Group 3 (bone metastasis rate of 5.8%) compared to Grade Group 2 (0.6%). 
Setting a threshold for BS of Grade Group ≥3 would have reduced the number of BS 
performed by 152 (34.7%), with a single false negative. This correlates with data used to 
inform the 2015 update to EAU guidelines(Heidenreich et al. 2014) and should encourage 
adoption of these proposed grading groups(Epstein et al. 2016).  
 
It should be noted that grade and stage data are not used in isolation in clinical 
management. We therefore tested the proof-of-principle of a new risk model incorporating 
the new Grade Group system, mpMRI and biochemical information. This refinement 
demonstrated promising results with a NPV of 100% for Risk Groups 1 and 2. Taken 
together, our data demonstrate that the combined use of more accurate mpMRI-staging 
and histological grade stratification better defines men who benefit most from bone staging 
investigations. These promising results show potential for reductions in the use of BS by up 
to a third while maintaining sensitivity and NPV above 97% and 99% respectively.  
 
The main limitation of our study is its retrospective nature and a selected population, only 
including men undergoing both mpMRI and BS. The relatively small absolute numbers of 
men with intermediate risk disease, or men with bone metastases in this cohort should lead 
to caution when interpreting sensitivity or specificity values in isolation.  Additionally, bone 
scintigraphy can be questioned as an ideal standard for diagnosing bone metastases, 
however, our data reflects current clinical practice and should be useful in guiding clinical 
management. PET-CT using fluorine or choline tracers has been shown to be a superior, 
albeit more expensive option for assessing metastatic bone involvement(Fuccio et al. 2012). 
Our results would require further validation in external cohorts in a prospective study and 
preferably using these modalities.  
 
Conclusion 
We demonstrate for the first time that the new histological Grade Group system and mpMRI 
staging more accurately identified men at risk of harbouring bone metastases. Importantly, 
our data strongly suggests that men without histology in Grade Group ≥3 and/or radiological 
T3 disease could safely avoid routine bone staging.  
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Table 1: Proposed new prostate cancer Risk group criteria taken from Gnanapragasam et al 
2016(Gnanapragasam et al. 2016) and using the new Grade Group system(Epstein et al. 
2016).  
 
 
 
 
  
New Risk Group Criteria 
 
1 Gleason 6 (Grade Group 1) AND PSA <10ng/ml 
AND Stage T1-2 
 
2 Gleason 3+4=7 (Grade Group 2) 
OR  
PSA 10-20ng/ml AND Stage T1-T2 
 
3 A combination of: Gleason 3+4=7 (Grade Group 
2), PSA 10-20ng/ml, Stage T1-T2  
OR  
Gleason 4+3=7 (Grade Group 3) AND Stage T1-
T2 
4 Any one of:  
Gleason 8 (Grade Group 4)  
OR  
PSA >20ng/ml  
OR  
Stage T3 
5 Any combination of: Gleason 8 (Grade Group 
4), PSA >20ng/ml, Stage T3  
OR  
Any Gleason 9-10 (Grade Group 5)  
OR  
Any Stage T4 
10 
 
Table 2A. The distribution and bone metastasis status of men categorised according to NICE 
classification, by clinical parameters alone and with mpMRI staging information integrated. 
P values are calculated with Pearson’s Chi-Squared tests using full contingency tables 
(eTable 1). n=438. 
 Clinical (NICE) Clinical (NICE) + mpMRI  
NICE 
risk 
group 
No 
bone 
mets 
Bone 
mets 
Bone 
mets 
rate (%) 
No 
bone 
mets 
Bone 
mets 
Bone 
mets rate 
(%) 
Low 12 0 0 4 0 0 
       
Int. 143 4 2.7 93 1 1.1 
       
High 246 33 11.8 304 36 10.6 
P Value   0.003   <0.001 
 
Table 2B. The distribution and bone metastasis status of men categorised by the new Grade 
Group score and the proposed Cambridge Risk score. P values are calculated with Pearson’s 
Chi-Squared tests using full contingency tables (eTable 1). n=438. 
 Grade Group score New Risk model  
Grade/
Risk 
Group 
No 
none 
mets 
Bone 
mets 
Bone mets 
rate (%) 
No bone 
mets 
Bone 
mets 
Bone 
mets 
rate (%) 
1 43 0 0 10 0 0 
2 108 1 0.9 40 0 0 
3 67 7 9.6 46 1 2.1 
4 82 9 9.9 129 8 5.8 
5 101 20 16.5 176 28 13.7 
   <0.001   0.004 
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Table 3. Summary statistics for each stratification system and risk group using the stated cut-
offs, as if it were a diagnostic test for bone metastasis. Comparisons (p values) are made 
against the current NICE classification (column 1), using McNemar’s test. The number of 
patients requiring BS using each classification is recorded in the first row.  
 NICE 
(BS for ≥ 
Intermedia
te-risk) 
NICE +mpMRI 
(BS for High-Risk 
men only) 
Grade Group 
(BS for Score  
≥  3) 
Grade Group 
(BS for  Score 
≥  4) 
New risk 
model  (BS for   
Risk Group ≥ 
3) 
New risk 
model (BS for    
Risk Group ≥ 
4) 
   P  
value 
 P 
value 
 P 
value 
 P 
value 
 P 
value 
BS performed 426 340 - 286 - 212 - 388 - 341 - 
Sensitivity 
(%) 
(95% CI) 
100 
(90.5, 100) 
97.3 
(85.8, 
99.9) 
0.32 97.3 
(85.8, 
99.9) 
0.32 
 
78.4 
(61.8, 
90.2) 
<0.01 100 
(90.5, 
100) 
- 97.3 
(85.8, 
99.9) 
0.32 
Specificity (%) 
(95% CI) 
3.0 
(1.6, 5.2) 
24.2 
(20.1, 
28.7) 
<0.01 37.7 
(32.9, 
42.6) 
<0.01 
 
54.4 
(49.3, 
59.3) 
<0.01 12.5 
(9.4, 
16.1) 
<0.01 
 
23.9 
(19.8, 
28.4) 
<0.01 
PPV (%) 
(95% CI) 
 
8.69 
(6.2, 11.8) 
10.6 
(7.5, 
14.4) 
<0.01 12.6 
(9.0, 
17.0) 
<0.01 13.7 
(9.4, 
19.1) 
<0.01 9.5 
(6.8, 
12.9) 
<0.01 10.6 
(7.5, 
14.3) 
<0.01 
NPV (%) 
(95%CI) 
100 
(73.5, 100) 
99.0 
(94.4, 
100) 
0.33 99.3 
(96.4, 
100) 
0.33 96.5 
(93.1, 
98.5) 
0.02 100 
(92.9, 
100) 
- 99.0 
(94.4, 
100) 
0.33 
 
 
 
 
 
  
12 
 
 
eFigure 1. 71 year old patient with clinically intermediate risk prostate cancer on 2008 
guidelines, up-risked by MRI.  
PSA 11.57, transperineal biopsy showed right side Grade Group 3 (Gleason 4+3=7) in 7 cores 
(5-25%) and left side Grade Group 2 (Gleason 3+4=7) in 6 cores (5-80%). A, B: MRI confirms 
bilateral tumour in the mid gland peripheral zone (arrows) with matching restricted 
diffusion (B), and irregularity consistent with early T3a disease on the right (white arrow in 
A), confirming high-risk disease. C-F: Subsequent bone scintigraphy shows focal tracer 
uptake in the right 5th posterior rib (arrow in C) and adjacent right anterior ribs (arrow in E), 
confirmed as sclerotic metastases on CT (D and F, respectively). 
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eFigure 2. 73 year old patient with clinically intermediate risk prostate cancer on updated 
guidelines, up-risked by MRI.  
PSA 12.25, transrectal ultrasound (TRUS) guided-biopsy showed right side Grade Group 3 
(Gleason 4+3=7) in 1/6 cores (5%), left side benign. A: MRI demonstrates a large tumour at 
the right apex (arrow), likely under-sampled at TRUS with filling in of the retro-prostatic 
angle and capsular irregularity, consistent with T3a high-risk disease. B: high b-value 
diffusion-weighted imaging shows a suspicious area of high signal adjacent to the right pubic 
symphysis (open arrow). C: bone scintigraphy (posterior view) confirms pubic metastasis 
and demonstrates additional area suspicious for metastasis in the posterior left 9th rib 
(arrows). 
14 
 
eTable 1. Contingency table showing the observed, expected and adjusted residual of bone metastasis in each of the grading and risk systems. 
P-Values calculated with Pearson’s Chi-Squared tests.  
      Grade Group   ‘Cambridge’ Risk Score   Clinical NICE (PSA & Gleason) 
Grade/Risk  
Group  
No  
Bone 
Mets 
Bone 
Mets 
Bone 
Mets  
Rate (%)  
No  
Bone 
Mets 
Bone 
Mets 
Bone 
Mets  
Rate (%)  
NICE  
Group 
No  
Bone 
Mets 
Bone 
Mets 
Bone 
Mets  
Rate (%) 
1 
Obs  43 0 
0 
 10 0 
0 
 
Low 
12 0 
0 
Exp  39.37 3.63  9.16 0.85  10.99 1.01 
Column %  10.72 0  2.49 0  2.99 0 
Adj. residual   2.1 -2.1   0.97 -0.97   1.07 -1.07 
2 
Obs  108 1 
0.92 
 40 0 
0 
     
Exp  99.79 9.21  36.62 3.38      
Column %  26.93 2.7  9.98 0      
Adj. residual   3.26 -3.26   2.02 -2.02        
3 
Obs  67 7 
9.56 
 46 1 
2.13 
 
Int. 
143 4 
2.72 
Exp  67.75 6.25  43.03 3.97  134.58 12.42 
Column %  16.71 18.92  11.47 2.79  35.66 10.81 
Adj. residual   -0.34 0.34   1.65 -1.65   3.06 -3.06 
4 
Obs  82 9 
9.89 
 129 8 
5.84 
     
Exp  83.31 7.69  125.43 11.57      
Column %  20.45 24.32  32.17 21.62      
Adj. residual   -0.56 0.56   1.32 -1.32        
5 
Obs  101 20 
16.53 
 176 28 
13.73 
 
High 
246 33 
11.83 
Exp  110.78 10.22  186.77 17.23  255.43 2357 
Column %  25.19 54.05  43.89 75.68  61.35 89.19 
Adj. residual   -3.76 3.76  -3.71 3.71   -3.37 3.37 
 p Value  <0.001  0.004  0.003 
